Showing results (1-10 of 156) with videos related to
Sort By:
Pageof 16
Blood|August 21, 2014
Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia AGiancarlo Castaman, Karin FijnvandraatBlood|February 23, 2013
Unraveling the genetics of inhibitors in hemophiliaSamantha C Gouw, Karin FijnvandraatSeminars in Thrombosis and Hemostasis|September 10, 2013
Identifying nongenetic risk factors for inhibitor development in severe hemophilia aSamantha C Gouw, Karin FijnvandraatSeminars in Thrombosis and Hemostasis|March 18, 2003
Immunobiology of inhibitor development in hemophilia AKarin Fijnvandraat, Wendy S Bril, Jan VoorbergEuropean Journal of Pediatrics|October 31, 2023
Shared decision-making between paediatric haematologists, children with sickle cell disease and their parents: an exploratory studyRicardo Wijngaarde, Mijra Koning, Karin Fijnvandraat, et al.Expert Review of Hematology|March 19, 2020
Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigmsDavid Lillicrap, Karin Fijnvandraat, Guy Young, et al.Journal of Clinical and Translational Research|March 16, 2019
Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant mannerJanneke I Loomans, Eva Stokhuijzen, Marjolein Peters, et al.Journal of Thrombosis and Haemostasis : JTH|May 15, 2025
Chromogenic vs one-stage assay to diagnose women and girls with hemophilia A-mapping global approaches and assessing challenges: communication from the SSCs of the ISTHLakshmi Srivaths, Joanna Larson, Karin Fijnvandraat, et al.Seminars in Thrombosis and Hemostasis|May 11, 2024
Nonsevere Hemophilia: The Need for a Renewed Focus and Improved OutcomesGerard Dolan, Karin Fijnvandraat, Peter J Lenting, et al.Seminars in Thrombosis and Hemostasis|May 6, 2016
Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia AGiancarlo Castaman, Corien Eckhardt, Alice van Velzen, et al.Pageof 16